about
DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriersAverage risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studiesAfter BRCA1 and BRCA2-what next? Multifactorial segregation analyses of three-generation, population-based Australian families affected by female breast cancer.Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriersThe androgen receptor CAG repeat polymorphism and modification of breast cancer risk in BRCA1 and BRCA2 mutation carriersGenome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer riskAssociation between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer.Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer.Modifiers of breast and ovarian cancer risks for BRCA1 and BRCA2 mutation carriersGermline mutations in RAD51D confer susceptibility to ovarian cancerLarge-scale genomic analyses link reproductive aging to hypothalamic signaling, breast cancer susceptibility and BRCA1-mediated DNA repairMosaic PPM1D mutations are associated with predisposition to breast and ovarian cancerIdentification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array.Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer.Prevalence and Penetrance of Major Genes and Polygenes for Colorectal Cancer.No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer.Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2.Comparison of 6q25 breast cancer hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC)Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics.Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation CarriersCommon genetic variants and modification of penetrance of BRCA2-associated breast cancerExploring the link between MORF4L1 and risk of breast cancer.Familial relative risks for breast cancer by pathological subtype: a population-based cohort studyCommon variants associated with breast cancer in genome-wide association studies are modifiers of breast cancer risk in BRCA1 and BRCA2 mutation carriersIncorporating tumour pathology information into breast cancer risk prediction algorithms.Attenuated familial adenomatous polyposis manifests as autosomal dominant late-onset colorectal cancer.Interplay between BRCA1 and RHAMM regulates epithelial apicobasal polarization and may influence risk of breast cancer.A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes.The KL-VS sequence variant of Klotho and cancer risk in BRCA1 and BRCA2 mutation carriersVariants in DNA double-strand break repair genes and breast cancer susceptibility.The contribution of germline BRCA1 and BRCA2 mutations to familial ovarian cancer: no evidence for other ovarian cancer-susceptibility genes.Breast-cancer risk in families with mutations in PALB2Common variants of the BRCA1 wild-type allele modify the risk of breast cancer in BRCA1 mutation carriers.Clinical software development for the Web: lessons learned from the BOADICEA project.Breast cancer risk and 6q22.33: combined results from Breast Cancer Association Consortium and Consortium of Investigators on Modifiers of BRCA1/2Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction.BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families.Evidence for SMAD3 as a modifier of breast cancer risk in BRCA2 mutation carriers.An international initiative to identify genetic modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: the Consortium of Investigators of Modifiers of BRCA1 and BRCA2 (CIMBA)Oral contraceptives and breast cancer risk in the international BRCA1/2 carrier cohort study: a report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS Collaborating Group.
P50
Q21144874-48C10D9E-1B1B-4301-B9A0-917F13D3F6BCQ24531993-62FB3D15-8A09-4A55-A1A5-BE51D60723E9Q24535695-E5302492-73D0-4FCB-A712-C82261935BE5Q24655824-0E1EEDAB-8666-4911-B839-3A99DF6537B4Q24797305-D3C7197F-4083-4295-8133-DD6AA0C44615Q27008356-8D244C33-4F33-45D3-917B-EA15BA2CFA86Q27851709-82370461-C0E5-4FFD-A90A-A8C9537FFF80Q27852185-A2EF90D2-C763-4219-A006-B2BD4EC03F93Q28067154-F23887CF-6DB6-4011-B9CD-6054B21307E4Q28245028-6E65C9D2-9DD7-4230-8628-8EB15F2046FAQ28267893-AA094BF9-047B-433C-BCF1-DE1EFE52A31FQ28388006-F8615635-59BC-4D98-99C2-EFB236A39208Q29417155-0ED99810-9BC9-4EB7-A084-C11232DDC310Q30252854-03F64E57-8D58-4401-A5B7-F8AA8A137369Q30275554-7E9722FA-7566-4FD3-9575-DD361E0A16E5Q30374367-8C87CC6F-768E-483F-AF25-D701DF040105Q31043651-ECBF856D-2D21-44E6-84A8-41F0DCE70555Q31082788-8C76E82A-2BD5-4665-8ECD-3B89E7236931Q31152672-55F89135-3B02-4E18-B62F-5F88A19FD78FQ33614244-CE133FD9-AE3F-4E92-A86B-004531DCFD09Q33614244-FE477BC5-92CB-46F1-9441-6A50083BA401Q33742096-57D70F65-3153-4EAA-A057-3A9AAF3572C8Q33863235-93C54324-1A80-4F9F-9B6C-78ED5E6E16CFQ33892928-D9FAF717-8778-4961-B0DF-1F41004D7869Q33947829-B2F5FD70-888F-45B7-BC86-F7A6910A7151Q34048046-F1B75674-1F1F-4AE6-8E5A-3F6331699692Q34075478-A12745D3-9A4E-42E5-BE17-7D6BB991B708Q34081324-643BC4AD-1C19-40BC-97E8-A33941AF0164Q34115258-645B61AE-E0FB-4CC6-AAB8-68B56EED6F24Q34115636-26CC7EDB-2438-4530-BC0C-9C893BD8E080Q34129771-04C1E67B-5AA1-47C5-AE27-5283367DE297Q34145680-23CD4731-AA86-48AF-93A6-EAD63BAE224FQ34148873-5E64CEB9-4B16-4A1C-B133-36A1756D2CD2Q34213403-C51E01E5-B20A-4F48-B297-960C926D5741Q34227099-2D89D97E-DD5D-4716-9CE5-14B253966D42Q34327945-1FD74051-B864-4B8A-BCE7-1070A9D302E4Q34394665-EB13DE49-B008-49A3-8F4E-B57FBBBF075AQ34480647-59D4AECB-D40F-4AE5-AEC9-7AAFAEF7DA75Q34613604-B81033D0-105F-466D-8835-EC9836590097Q34623703-A124C5D2-E512-4B08-B0C8-7F168E1B1338
P50
description
researcher
@en
name
Antonis C Antoniou
@en
type
label
Antonis C Antoniou
@en
prefLabel
Antonis C Antoniou
@en
P31
P496
0000-0001-9223-3116